• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, February 27, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

UToledo awarded Department of Defense funding to advance promising new chemotherapy

Bioengineer by Bioengineer
January 25, 2021
in Chemistry
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Daniel Miller / UToledo

Researchers at The University of Toledo have received a three-year funding award of $1.4 million from the U.S. Department of Defense for a pre-clinical study of promising new chemotherapy aimed at triple negative breast cancer.

The treatment, which relies on a unique cell death pathway, could prove to be critical in overcoming the multidrug resistance that often characterizes and limits the therapy options for triple negative breast cancer.

“Triple negative breast cancer is perhaps the most aggressive, recurrent and difficult-to-treat breast cancer. Patients with residual, resistant tumors have a six times higher rate of distant recurrence and are 12 times more likely to die. Treatment options are limited and for many patients, the prognosis is extremely poor,” said Dr. Amit K. Tiwari, an associate professor in the UToledo College of Pharmacy and Pharmaceutical Sciences who identified the therapy and is the principal investigator. “Drug discovery is a long road but we have come a significant distance already. We have found a molecule that is safe, effective and can overcome resistance to other therapeutics.”

Most other chemotherapy drugs kill cancer cells by apoptosis, a process that programs the cells to shrink and break down on multiple fault lines. The compound discovered by Tiwari instead causes cancer cells to swell and burst. When the cells rupture, they release markers that help activate the body’s immune system to target and kill neighboring cancer cells more effectively.

“Our research has shown this drug is killing the cancer cells in multiple different ways,” Tiwari said. “Even the most resistant cancer cells are responding.”

Triple negative breast cancer accounts for roughly 15% to 20% of all breast cancer cases in the United States. Because the cancer cells present in this type of breast cancer don’t share the receptors that many other forms of breast cancer have, it does not respond to hormonal therapies or therapies that target HER2 receptors.

While traditional chemotherapy may initially work, many patients soon develop resistance to those therapies, allowing the cancer to spread to distant organs unchecked. Tiwari’s research has shown UToledo’s drug appears to be able to treat triple negative breast cancer even in cases where the cancer cells have developed mutations in the apoptosis signaling pathway and thus resistance to conventional chemotherapy.

The UToledo team has already shown the drug works in animal models and human triple negative breast cancer cells in the lab. With the Department of Defense funding, researchers will seek to understand the chemical structures necessary to produce unique non-apoptotic cell death and optimize additional analogues of the lead molecule, continue to evaluate its action on patient-derived tumors and better understand the protein targets that induce cancer cell death.

Prior research suggests UToledo’s compound acts on a protein in the mitochondria called Dynamin related protein 1, which is often highly expressed in triple negative breast cancer. Better understanding the mechanism as how targeting mitochondrial protein leads to unique cell death is one of the primary goals of the Department of Defense funding in order to advance the research to clinical trials in humans.

Uncovering new treatments for drug-resistant cancer is one of Tiwari’s primary aims. He has devoted more than a decade to studying multidrug resistance in various types of cancers and finding innovative ways to overcome those challenges.

In 2018, Tiwari received nearly $450,000 in grant funding from Susan G. Komen Northwest Ohio to support drug development research. The data generated from that funding helped secure the larger Department of Defense funding.

“What we’re doing in this drug resistance is extremely important. Very few people work in this area because of the complexity,” Tiwari said. “Most of the molecules that are developed to target triple negative breast cancers are focused on early-stage cancers. I want my research to give patients hope that there may soon be treatments even at the later stage of the disease.”

###

Tiwari’s research is supported by the U.S. Department of Defense under the award number W81XWH-21-1-0053. The views expressed in this article are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense or the U.S. Government.

Media Contact
Tyrel Linkhorn
[email protected]

Tags: Breast CancercancerMedicine/HealthPharmaceutical SciencePharmaceutical Sciences
Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

C-Path and Global Partners launch Ataxia Consortium

February 26, 2021
IMAGE

Quantum quirk yields giant magnetic effect, where none should exist

February 26, 2021

Meteorites remember conditions of stellar explosions

February 26, 2021

How photoblueing disturbs microscopy

February 26, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    638 shares
    Share 255 Tweet 160
  • People living with HIV face premature heart disease and barriers to care

    82 shares
    Share 33 Tweet 21
  • Global analysis suggests COVID-19 is seasonal

    38 shares
    Share 15 Tweet 10
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Technology/Engineering/Computer ScienceMedicine/HealthcancerInfectious/Emerging DiseasesEcology/EnvironmentMaterialsCell BiologyClimate ChangeBiologyGeneticsPublic HealthChemistry/Physics/Materials Sciences

Recent Posts

  • Predicts the onset of Alzheimer’s Disease (AD) using deep learning-based Splice-AI
  • When foams collapse (and when they don’t)
  • UTA researcher explores effects of trauma at the cellular, tissue levels of the brain
  • Picture books can boost physical activity for youth with autism
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In